Concepedia

Xuejun Liu

XL

10

Publications

427

Citations

10

H-Index

2010

Active since

Affiliations

Bristol-Myers Squibb (Germany)(Current)

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Sweden)

University of North Carolina at Chapel Hill

Vanderbilt University Medical Center

Xuejun Liu is an author at Bristol-Myers Squibb (Germany) specializing in unemployment, workforce development, and human resource management.

ORCID

Top concepts

Publications per year

2010–2025

10

Publications

10

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Ming Chang, Mayumi Hasegawa et al. · Diabetes Obesity and Metabolism · 2011 · 110 citations

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

Sreeneeranj Kasichayanula, Xuejun Liu, W. C. Shyu et al. · Diabetes Obesity and Metabolism · 2010 · 86 citations

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

Sreeneeranj Kasichayanula, Xuejun Liu, Steven C. Griffen et al. · Diabetes Obesity and Metabolism · 2012 · 63 citations

Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

Sreeneeranj Kasichayanula, Xuejun Liu, W. Zhang et al. · Diabetes Obesity and Metabolism · 2011 · 47 citations

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 29 citations · Full text

Rows per page

1–5 of 10